{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:11:50Z","timestamp":1790039510581,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijcard.2025.133327","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:49:11Z","timestamp":1745927351000},"page":"133327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of a personalized, strike early and strong approach on non-HDL-cholesterol levels and outcome in patients with acute myocardial infarction"],"prefix":"10.1016","volume":"433","author":[{"given":"Giuseppe","family":"Patti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cumitini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mennuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Grisafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2025.133327_bb0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ijcard.2025.133327_bb0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"39","key":"10.1016\/j.ijcard.2025.133327_bb0015","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur. Heart J."},{"issue":"39","key":"10.1016\/j.ijcard.2025.133327_bb0020","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"10106","key":"10.1016\/j.ijcard.2025.133327_bb0025","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"FOURIER investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijcard.2025.133327_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a Prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2025.133327_bb0035","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a Meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133327_bb0040","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and Meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijcard.2025.133327_bb0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ehjcvp\/pvac049","article-title":"Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials","volume":"9","author":"Patti","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"44","key":"10.1016\/j.ijcard.2025.133327_bb0050","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093\/eurheartj\/ehz455. Erratum in","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133327_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107141","article-title":"The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS EuroPath IV project","volume":"148","author":"Laufs","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2025.133327_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131659","article-title":"Achievement of target LDL-cholesterol level in patients with acute coronary syndrome undergoing percutaneous coronary intervention: the JET-LDL registry","volume":"397","author":"Ferlini","year":"2024","journal-title":"Int. J. Cardiol."},{"issue":"29","key":"10.1016\/j.ijcard.2025.133327_bb0065","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ijcard.2025.133327_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.athplu.2022.07.024","article-title":"Low-density lipoprotein cholesterol goal attainment in Germany: results from the DA VINCI study","volume":"50","author":"Gouni-Berthold","year":"2022","journal-title":"Atheroscler. Plus"},{"issue":"2","key":"10.1016\/j.ijcard.2025.133327_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133327_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"6","key":"10.1016\/j.ijcard.2025.133327_bb0085","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MOL.0000000000000237","article-title":"Non-high-density lipoprotein cholesterol: current status as cardiovascular marker","volume":"26","author":"Verbeek","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133327_bb0090","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1373\/clinchem.2010.154773","article-title":"Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population","volume":"57","author":"Van Deventer","year":"2011","journal-title":"Clin. Chem."},{"issue":"27","key":"10.1016\/j.ijcard.2025.133327_bb0095","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133327_bb0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.amjcard.2015.05.011","article-title":"Frequency of attainment of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in cardiovascular clinical practice (from the National Cardiovascular Data Registry PINNACLE registry)","volume":"116","author":"Spinler","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2025.133327_bb0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133327_bb0110","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","article-title":"Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial","volume":"49","author":"Patti","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133327_bb0115","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"7","key":"10.1016\/j.ijcard.2025.133327_bb0120","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"10","key":"10.1016\/j.ijcard.2025.133327_bb0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamacardio.2023.2731","article-title":"Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated Meta-regression analysis","volume":"8","author":"Iatan","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"18","key":"10.1016\/j.ijcard.2025.133327_bb0130","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ijcard.2025.133327_bb0135","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.ijcard.2025.133327_bb0140","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"27","key":"10.1016\/j.ijcard.2025.133327_bb0145","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment Trialists collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.ijcard.2025.133327_bb0150","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"15","key":"10.1016\/j.ijcard.2025.133327_bb0155","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacc.2015.02.017","article-title":"TNT steering committee and investigators. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial","volume":"65","author":"Bangalore","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"27","key":"10.1016\/j.ijcard.2025.133327_bb0160","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehy209","article-title":"Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes","volume":"39","author":"Clark","year":"2018","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325003705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325003705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:57:55Z","timestamp":1758193075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325003705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S0167527325003705"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133327","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a personalized, strike early and strong approach on non-HDL-cholesterol levels and outcome in patients with acute myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"133327"}}